AAAAAA

   
Results: 1-24 |
Results: 24
Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker
Authors: ten Berge, RL Oudejans, JJ Dukers, DF Meijer, JWR Ossenkoppele, GJ Meijer, CJLM
Citation: Rl. Ten Berge et al., Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker, LEUKEMIA, 15(3), 2001, pp. 458-464
Functional characterization of minimal residual disease for P-glycoproteinand multidrug resistance protein activity in acute myeloid leukemia
Authors: van der Pol, MA Pater, JM Feller, N Westra, AH van Stijn, A Ossenkoppele, GJ Broxterman, HJ Schuurhuis, GJ
Citation: Ma. Van Der Pol et al., Functional characterization of minimal residual disease for P-glycoproteinand multidrug resistance protein activity in acute myeloid leukemia, LEUKEMIA, 15(10), 2001, pp. 1554-1563
Monocyte-chemoattractant-protein-1-mediated migration of human monocytes towards blasts from patients with acute myeloid leukemia
Authors: Legdeur, MCJC Broekhoven, MG Schuurhuis, GJ Beelen, RHJ Ossenkoppele, GJ
Citation: Mcjc. Legdeur et al., Monocyte-chemoattractant-protein-1-mediated migration of human monocytes towards blasts from patients with acute myeloid leukemia, CANCER IMMU, 50(1), 2001, pp. 16-22
Storage of unprocessed G-CSF-mobilized whole blood in a modified Leibovitz's L15 medium preserves clonogenic capacity for at least 7 days
Authors: de Kreuk, AM Jonkhoff, AR Zevenbergen, Z Hendriks, ECM Schuurhuis, GJ Ossenkoppele, GJ Drager, AM van Oostveen, JW Huijgens, PC
Citation: Am. De Kreuk et al., Storage of unprocessed G-CSF-mobilized whole blood in a modified Leibovitz's L15 medium preserves clonogenic capacity for at least 7 days, BONE MAR TR, 28(2), 2001, pp. 145-155
High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma
Authors: Huijgens, PC Dekker-van Roessel, HM Jonkhoff, AR Admiraal, GC Zweegman, S Schuurhuis, GJ Ossenkoppele, GJ
Citation: Pc. Huijgens et al., High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma, BONE MAR TR, 27(9), 2001, pp. 925-931
Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants
Authors: Schuurhuis, GJ Muijen, MM Oberink, JW de Boer, F Ossenkoppele, GJ Broxterman, HJ
Citation: Gj. Schuurhuis et al., Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants, BONE MAR TR, 27(5), 2001, pp. 487-498
In-vitro cellular drug resistance in acute non-lymhoblastic leukemia: Comparisons between adults and children
Authors: de Haas, TGKJ Zwaan, CM Wondergem, MJ Pieters, R Kaspers, GJL Loonen, AH Rottier, MMA Wunsche, R Creutzig, U Bartl, S Hahlen, K Broxterman, HJ Ossenkoppele, GJ Veerman, AJP
Citation: Tgkj. De Haas et al., In-vitro cellular drug resistance in acute non-lymhoblastic leukemia: Comparisons between adults and children, HEMAT BLOOD, 40, 2001, pp. 244-250
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia
Authors: van der Kolk, DM de Vries, EGE van Putten, WLJ Verdonck, LF Ossenkoppele, GJ Verhoef, GEG Vellenga, E
Citation: Dm. Van Der Kolk et al., P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia, CLIN CANC R, 6(8), 2000, pp. 3205-3214
P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy
Authors: Broxterman, HJ Sonneveld, P van Putten, WJL Lankelma, J Eekman, CA Ossenkoppele, GJ Pinedo, HM Lowenberg, B Schuurhuis, GJ
Citation: Hj. Broxterman et al., P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy, LEUKEMIA, 14(6), 2000, pp. 1018-1024
Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests
Authors: Janssen, JJWM van Rijn, RS van der Holt, B Schuurhuis, GJ Vellenga, E Verhoef, GEG Ossenkoppele, GJ van den Berg, E Hagemeijer, A Slater, R Nieuwint, AWM Cornelissen, JJ
Citation: Jjwm. Janssen et al., Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests, BONE MAR TR, 25(11), 2000, pp. 1147-1155
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occursbefore dissemination
Authors: ten Berge, RL Oudejans, JJ Ossenkoppele, GJ Pulford, K Willemze, R Falini, B Chott, A Meijer, CJLM
Citation: Rl. Ten Berge et al., ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occursbefore dissemination, J CLIN PATH, 53(6), 2000, pp. 445-450
Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells
Authors: Xie, Y de Winter, JP Waisfisz, Q Nieuwint, AWM Scheper, RJ Arwert, F Hoatlin, ME Ossenkoppele, GJ Schuurhuis, GJ Joenje, H
Citation: Y. Xie et al., Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells, BR J HAEM, 111(4), 2000, pp. 1057-1064
Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity
Authors: van der Kolk, DM Vellenga, E van der Veen, AY Noordhoek, L Timmer-Bosscha, H Ossenkoppele, GJ Raymakers, RA Muller, M van den Berg, E de Vries, EGE
Citation: Dm. Van Der Kolk et al., Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity, BLOOD, 95(11), 2000, pp. 3514-3519
Stem cell transplantations in patients with malignant lymphoma: Costs in aDutch university hospital in the period 1984-1995
Authors: Uyl-De Groot, CA Ossenkoppele, GJ Buijt, I Huijgens, PC
Citation: Ca. Uyl-de Groot et al., Stem cell transplantations in patients with malignant lymphoma: Costs in aDutch university hospital in the period 1984-1995, J HEMATH ST, 8(6), 1999, pp. 619-625
Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma
Authors: Uyl-de Groot, CA Ossenkoppele, GJ Buijt, I Huijgens, PC
Citation: Ca. Uyl-de Groot et al., Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma, PHARMACOECO, 15(3), 1999, pp. 305-311
Guillain-Barre syndrome after autologous peripheral blood stem cell transplantation for CML
Authors: Janssen, JJWM Tissingh, G Ossenkoppele, GJ
Citation: Jjwm. Janssen et al., Guillain-Barre syndrome after autologous peripheral blood stem cell transplantation for CML, EUR J HAEMA, 63(5), 1999, pp. 358-359
A randomized study of granulocyte colony-stimulating factor applied duringand after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group
Authors: Ossenkoppele, GJ van der Holt, B Verhoef, GEG Daenen, SMGJ Verdonck, LF Sonneveld, P Wijermans, PW van der Lelie, J van Putten, WLJ Lowenberg, B
Citation: Gj. Ossenkoppele et al., A randomized study of granulocyte colony-stimulating factor applied duringand after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group, LEUKEMIA, 13(8), 1999, pp. 1207-1213
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia
Authors: Broxterman, HJ Sonneveld, P Pieters, R Lankelma, J Eekman, CA Loonen, AH Schoester, M Ossenkoppele, GJ Lowenberg, B Pinedo, HM Schuurhuis, GJ
Citation: Hj. Broxterman et al., Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia, LEUKEMIA, 13(2), 1999, pp. 258-265
Chronic myeloid leukemia from basics to bedside
Authors: Thijsen, SFT Schuurhuis, GJ van Oostveen, JW Ossenkoppele, GJ
Citation: Sft. Thijsen et al., Chronic myeloid leukemia from basics to bedside, LEUKEMIA, 13(11), 1999, pp. 1646-1674
Fluconazole versus itraconazole for the prevention of fungal infections inhaemato-oncology
Authors: Huijgens, PC Simoons-Smit, AM van Loenen, AC Prooy, E van Tinteren, H Ossenkoppele, GJ Jonkhoff, AR
Citation: Pc. Huijgens et al., Fluconazole versus itraconazole for the prevention of fungal infections inhaemato-oncology, J CLIN PATH, 52(5), 1999, pp. 376-380
A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas
Authors: Dukers, DF ten Berge, RL Oudejans, JJ Pulford, K Hayes, D Misere, JFMM Ossenkoppele, GJ Jaspars, LH Willemze, R Meijer, CJLM
Citation: Df. Dukers et al., A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas, J CLIN PATH, 52(2), 1999, pp. 129-136
Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
Authors: Thijsen, SFT Schuurhuis, GJ van Oostveen, JW Theijsmeijer, AP van der Hem, KG Odding, JH Drager, AM Ossenkoppele, GJ
Citation: Sft. Thijsen et al., Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors, BR J CANC, 79(9-10), 1999, pp. 1406-1412
Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma
Authors: ten Berge, RL Dukers, DF Oudejans, JJ Pulford, K Ossenkoppele, GJ de Jong, D Misere, JFMM Meijer, CJLM
Citation: Rl. Ten Berge et al., Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma, BLOOD, 93(8), 1999, pp. 2688-2696
Costs of intensive treatment and follow-up of patients with multiple myeloma
Authors: Buijt, I Ossenkoppele, GJ Uyl-de Groot, CA Huijgens, PC
Citation: I. Buijt et al., Costs of intensive treatment and follow-up of patients with multiple myeloma, ANTI-CANC D, 9(10), 1998, pp. 889-897
Risultati: 1-24 |